Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. (Q50670242)
Jump to navigation
Jump to search
scientific article published on 9 June 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. |
scientific article published on 9 June 2014 |
Statements
1 reference
Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. (English)
1 reference
1 reference
Ajay Vora
1 reference
Nick Goulden
1 reference
Chris Mitchell
1 reference
Jeremy Hancock
1 reference
Rachael Hough
1 reference
Clare Rowntree
1 reference
Rachel Wade
1 reference
9 June 2014
1 reference
15
1 reference
809-818
1 reference
8
1 reference
Identifiers
1 reference